| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | GTPase activator activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D FLCN TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 1.31e-13 | 279 | 50 | 13 | GO:0005096 |
| GeneOntologyMolecularFunction | GTPase regulator activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D OBSCN FLCN TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 1.57e-11 | 507 | 50 | 14 | GO:0030695 |
| GeneOntologyMolecularFunction | nucleoside-triphosphatase regulator activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D OBSCN FLCN TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 1.57e-11 | 507 | 50 | 14 | GO:0060589 |
| GeneOntologyMolecularFunction | enzyme activator activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D FLCN TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 5.35e-09 | 656 | 50 | 13 | GO:0008047 |
| GeneOntologyMolecularFunction | enzyme regulator activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D OBSCN FLCN TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 6.44e-06 | 1418 | 50 | 14 | GO:0030234 |
| GeneOntologyMolecularFunction | molecular function activator activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D FLCN TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 7.38e-06 | 1233 | 50 | 13 | GO:0140677 |
| GeneOntologyMolecularFunction | glycerol kinase activity | 1.84e-05 | 3 | 50 | 2 | GO:0004370 | |
| GeneOntologyBiologicalProcess | activation of GTPase activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 1.51e-17 | 109 | 48 | 12 | GO:0090630 |
| GeneOntologyBiologicalProcess | positive regulation of GTPase activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 2.74e-13 | 244 | 48 | 12 | GO:0043547 |
| GeneOntologyBiologicalProcess | regulation of GTPase activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 1.14e-11 | 335 | 48 | 12 | GO:0043087 |
| GeneOntologyBiologicalProcess | positive regulation of hydrolase activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 1.11e-09 | 499 | 48 | 12 | GO:0051345 |
| GeneOntologyBiologicalProcess | regulation of hydrolase activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 5.55e-07 | 878 | 48 | 12 | GO:0051336 |
| GeneOntologyBiologicalProcess | glycerol-3-phosphate metabolic process | 1.40e-06 | 10 | 48 | 3 | GO:0006072 | |
| GeneOntologyBiologicalProcess | alditol phosphate metabolic process | 2.56e-06 | 12 | 48 | 3 | GO:0052646 | |
| GeneOntologyBiologicalProcess | positive regulation of catalytic activity | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 2.90e-06 | 1028 | 48 | 12 | GO:0043085 |
| GeneOntologyBiologicalProcess | glycerol-3-phosphate biosynthetic process | 1.59e-05 | 3 | 48 | 2 | GO:0046167 | |
| GeneOntologyBiologicalProcess | positive regulation of molecular function | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 7.89e-05 | 1430 | 48 | 12 | GO:0044093 |
| GeneOntologyBiologicalProcess | glycerol catabolic process | 7.91e-05 | 6 | 48 | 2 | GO:0019563 | |
| GeneOntologyBiologicalProcess | alditol catabolic process | 1.11e-04 | 7 | 48 | 2 | GO:0019405 | |
| GeneOntologyBiologicalProcess | triglyceride metabolic process | 2.16e-04 | 127 | 48 | 4 | GO:0006641 | |
| GeneOntologyBiologicalProcess | triglyceride biosynthetic process | 2.41e-04 | 52 | 48 | 3 | GO:0019432 | |
| GeneOntologyBiologicalProcess | polyol catabolic process | 3.45e-04 | 12 | 48 | 2 | GO:0046174 | |
| GeneOntologyBiologicalProcess | glycerolipid biosynthetic process | 3.87e-04 | 268 | 48 | 5 | GO:0045017 | |
| GeneOntologyBiologicalProcess | neutral lipid biosynthetic process | 4.26e-04 | 63 | 48 | 3 | GO:0046460 | |
| GeneOntologyBiologicalProcess | acylglycerol biosynthetic process | 4.26e-04 | 63 | 48 | 3 | GO:0046463 | |
| GeneOntologyBiologicalProcess | glycerolipid metabolic process | 4.58e-04 | 429 | 48 | 6 | GO:0046486 | |
| GeneOntologyBiologicalProcess | acylglycerol metabolic process | 4.73e-04 | 156 | 48 | 4 | GO:0006639 | |
| GeneOntologyBiologicalProcess | neutral lipid metabolic process | 4.96e-04 | 158 | 48 | 4 | GO:0006638 | |
| GeneOntologyCellularComponent | dynactin complex | 1.37e-04 | 8 | 47 | 2 | GO:0005869 | |
| MousePheno | oligozoospermia | 6.17e-06 | 384 | 27 | 7 | MP:0002687 | |
| MousePheno | decreased male germ cell number | 1.89e-05 | 640 | 27 | 8 | MP:0004901 | |
| MousePheno | decreased germ cell number | 3.15e-05 | 687 | 27 | 8 | MP:0002209 | |
| MousePheno | decreased sperm mitochondrial sheath size | 5.36e-05 | 6 | 27 | 2 | MP:0014464 | |
| MousePheno | abnormal sperm mitochondrial sheath size | 5.36e-05 | 6 | 27 | 2 | MP:0014462 | |
| MousePheno | abnormal sperm number | 1.39e-04 | 624 | 27 | 7 | MP:0002673 | |
| MousePheno | abnormal male germ cell morphology | 1.53e-04 | 859 | 27 | 8 | MP:0006362 | |
| MousePheno | abnormal spermatogenesis | 2.28e-04 | 910 | 27 | 8 | MP:0001156 | |
| MousePheno | abnormal germ cell morphology | 2.98e-04 | 946 | 27 | 8 | MP:0002208 | |
| MousePheno | abnormal foam cell morphology | 3.15e-04 | 954 | 27 | 8 | MP:0009840 | |
| MousePheno | abnormal gametes | 5.66e-04 | 785 | 27 | 7 | MP:0001124 | |
| MousePheno | abnormal male reproductive system physiology | 5.94e-04 | 1329 | 27 | 9 | MP:0003698 | |
| MousePheno | abnormal gametogenesis | 6.83e-04 | 1070 | 27 | 8 | MP:0001929 | |
| MousePheno | abnormal sperm motility | 9.08e-04 | 401 | 27 | 5 | MP:0002674 | |
| MousePheno | teratozoospermia | 9.81e-04 | 408 | 27 | 5 | MP:0005578 | |
| Domain | RabGAP-TBC | TBC1D3E TBC1D3H TBC1D3L TBC1D3D TBC1D28 TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 4.61e-21 | 53 | 48 | 12 | PF00566 |
| Domain | TBC_RABGAP | TBC1D3E TBC1D3H TBC1D3L TBC1D3D TBC1D28 TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 7.55e-21 | 55 | 48 | 12 | PS50086 |
| Domain | Rab-GTPase-TBC_dom | TBC1D3E TBC1D3H TBC1D3L TBC1D3D TBC1D28 TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 7.55e-21 | 55 | 48 | 12 | IPR000195 |
| Domain | TBC | TBC1D3E TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D26 TBC1D3K TBC1D3F | 2.55e-19 | 49 | 48 | 11 | SM00164 |
| Domain | Arp1 | 6.47e-06 | 2 | 48 | 2 | IPR029909 | |
| Domain | Carb_kinase_FGGY_CS | 1.94e-05 | 3 | 48 | 2 | IPR018483 | |
| Domain | Glycerol_kin | 3.87e-05 | 4 | 48 | 2 | IPR005999 | |
| Domain | FGGY_KINASES_2 | 6.44e-05 | 5 | 48 | 2 | PS00445 | |
| Domain | FGGY_KINASES_1 | 6.44e-05 | 5 | 48 | 2 | PS00933 | |
| Domain | Carb_kinase_FGGY_C | 6.44e-05 | 5 | 48 | 2 | IPR018485 | |
| Domain | FGGY_C | 9.64e-05 | 6 | 48 | 2 | PF02782 | |
| Domain | Carb_kinase_FGGY_N | 9.64e-05 | 6 | 48 | 2 | IPR018484 | |
| Domain | Carb_kinase_FGGY | 1.35e-04 | 7 | 48 | 2 | IPR000577 | |
| Domain | FGGY_N | 1.35e-04 | 7 | 48 | 2 | PF00370 | |
| Domain | Actin_CS | 7.58e-04 | 16 | 48 | 2 | IPR004001 | |
| Domain | ACTINS_2 | 8.58e-04 | 17 | 48 | 2 | PS00432 | |
| Domain | Actin/actin-like_CS | 9.64e-04 | 18 | 48 | 2 | IPR020902 | |
| Domain | ACTINS_ACT_LIKE | 1.08e-03 | 19 | 48 | 2 | PS01132 | |
| Domain | Actin | 2.87e-03 | 31 | 48 | 2 | IPR004000 | |
| Domain | Actin | 2.87e-03 | 31 | 48 | 2 | PF00022 | |
| Domain | ACTIN | 2.87e-03 | 31 | 48 | 2 | SM00268 | |
| Pathway | WP_17Q12_COPY_NUMBER_VARIATION_SYNDROME | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D3K | 1.30e-12 | 99 | 34 | 9 | M46448 |
| Pathway | WP_TRIACYLGLYCERIDE_SYNTHESIS | 2.42e-07 | 23 | 34 | 4 | MM15890 | |
| Pathway | WP_TRIACYLGLYCERIDE_SYNTHESIS | 2.90e-07 | 24 | 34 | 4 | M39692 | |
| Pathway | REACTOME_TRIGLYCERIDE_BIOSYNTHESIS | 2.78e-06 | 12 | 34 | 3 | MM15447 | |
| Pathway | REACTOME_TRIGLYCERIDE_BIOSYNTHESIS | 4.58e-06 | 14 | 34 | 3 | M619 | |
| Pathway | KEGG_GLYCEROLIPID_METABOLISM | 5.53e-06 | 49 | 34 | 4 | M15902 | |
| Pathway | KEGG_PPAR_SIGNALING_PATHWAY | 2.18e-05 | 69 | 34 | 4 | M13088 | |
| Pathway | REACTOME_TRIGLYCERIDE_METABOLISM | 2.20e-05 | 23 | 34 | 3 | MM15575 | |
| Pathway | WP_PPAR_SIGNALING_PATHWAY | 2.73e-05 | 73 | 34 | 4 | MM15995 | |
| Pathway | WP_FATTY_ACID_BETAOXIDATION | 7.29e-05 | 34 | 34 | 3 | M39596 | |
| Pathway | WP_FATTY_ACID_BETAOXIDATION | 7.29e-05 | 34 | 34 | 3 | MM15937 | |
| Pathway | REACTOME_TRIGLYCERIDE_METABOLISM | 1.02e-04 | 38 | 34 | 3 | M27856 | |
| Pathway | WP_PPAR_SIGNALING | 5.53e-04 | 67 | 34 | 3 | M39553 | |
| Pathway | WP_GLYCEROLIPIDS_AND_GLYCEROPHOSPHOLIPIDS | 1.27e-03 | 22 | 34 | 2 | M39362 | |
| Pathway | WP_GLYCEROLIPIDS_AND_GLYCEROPHOSPHOLIPIDS | 1.38e-03 | 23 | 34 | 2 | MM15993 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_SOD1_TO_RETROGRADE_AXONAL_TRANSPORT | 1.91e-03 | 27 | 34 | 2 | M47755 | |
| Pathway | WP_GLYCEROPHOSPHOLIPID_BIOSYNTHETIC_PATHWAY | 2.35e-03 | 30 | 34 | 2 | M39592 | |
| Pubmed | TBC1D3, a hominoid oncoprotein, is encoded by a cluster of paralogues located on chromosome 17q12. | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 3.38e-32 | 11 | 53 | 11 | 16863688 |
| Pubmed | DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. | 2.10e-11 | 74 | 53 | 7 | 16625196 | |
| Pubmed | 1.34e-08 | 4 | 53 | 3 | 8406013 | ||
| Pubmed | PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. | 1.34e-08 | 4 | 53 | 3 | 12359748 | |
| Pubmed | 3.33e-08 | 5 | 53 | 3 | 12604796 | ||
| Pubmed | 3.33e-08 | 5 | 53 | 3 | 8471161 | ||
| Pubmed | 2.28e-06 | 2 | 53 | 2 | 30662012 | ||
| Pubmed | 2.28e-06 | 2 | 53 | 2 | 7696711 | ||
| Pubmed | 6.83e-06 | 3 | 53 | 2 | 28852571 | ||
| Pubmed | Diversity of human copy number variation and multicopy genes. | 6.83e-06 | 3 | 53 | 2 | 21030649 | |
| Pubmed | Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. | 2.27e-05 | 5 | 53 | 2 | 19270708 | |
| Pubmed | A-kinase anchoring protein 4 binding proteins in the fibrous sheath of the sperm flagellum. | 2.27e-05 | 5 | 53 | 2 | 12606363 | |
| Pubmed | The glycerol kinase gene family: structure of the Xp gene, and related intronless retroposons. | 2.27e-05 | 5 | 53 | 2 | 7987308 | |
| Pubmed | 3.95e-05 | 43 | 53 | 3 | 19077034 | ||
| Pubmed | 4.76e-05 | 7 | 53 | 2 | 10444329 | ||
| Pubmed | Interactions between the evolutionarily conserved, actin-related protein, Arp11, actin, and Arp1. | 4.76e-05 | 7 | 53 | 2 | 12857853 | |
| Pubmed | A Cellular Mechanism to Detect and Alleviate Reductive Stress. | 8.15e-05 | 9 | 53 | 2 | 32941802 | |
| Pubmed | Structural basis and regulation of the reductive stress response. | 1.02e-04 | 10 | 53 | 2 | 34562363 | |
| Pubmed | 1.02e-04 | 10 | 53 | 2 | 9060410 | ||
| Pubmed | 1.37e-04 | 750 | 53 | 7 | 11230166 | ||
| Pubmed | Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. | 2.05e-04 | 14 | 53 | 2 | 16682971 | |
| Pubmed | 3.05e-04 | 17 | 53 | 2 | 17496333 | ||
| Pubmed | Animal Models of Congenital Cardiomyopathies Associated With Mutations in Z-Line Proteins. | 3.83e-04 | 19 | 53 | 2 | 27171814 | |
| Pubmed | Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. | 4.70e-04 | 21 | 53 | 2 | 22190037 | |
| Pubmed | 5.01e-04 | 101 | 53 | 3 | 10997877 | ||
| Pubmed | 5.79e-04 | 250 | 53 | 4 | 18660489 | ||
| Pubmed | Blood pressure is regulated by an alpha1D-adrenergic receptor/dystrophin signalosome. | 7.80e-04 | 27 | 53 | 2 | 18468998 | |
| Pubmed | 8.40e-04 | 28 | 53 | 2 | 8944226 | ||
| Pubmed | An improved smaller biotin ligase for BioID proximity labeling. | 8.89e-04 | 123 | 53 | 3 | 26912792 | |
| Pubmed | 9.53e-04 | 497 | 53 | 5 | 23414517 | ||
| Pubmed | 9.64e-04 | 30 | 53 | 2 | 19936222 | ||
| Pubmed | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. | 1.10e-03 | 32 | 53 | 2 | 23535730 | |
| Pubmed | ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure. | 1.36e-03 | 315 | 53 | 4 | 26777405 | |
| Pubmed | Biological, clinical and population relevance of 95 loci for blood lipids. | 1.46e-03 | 146 | 53 | 3 | 20686565 | |
| Pubmed | 1.47e-03 | 37 | 53 | 2 | 35863637 | ||
| Interaction | CLIC3 interactions | 1.79e-05 | 63 | 50 | 4 | int:CLIC3 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr17q12 | TBC1D3E TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3I TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 1.96e-17 | 149 | 53 | 11 | chr17q12 |
| Cytoband | 17q12 | 1.11e-07 | 99 | 53 | 5 | 17q12 | |
| Cytoband | 17p11.2 | 8.41e-04 | 159 | 53 | 3 | 17p11.2 | |
| GeneFamily | Glycerol kinases | 2.31e-05 | 6 | 23 | 2 | 568 | |
| Coexpression | NAKAYA_B_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP | 5.16e-06 | 367 | 49 | 7 | M41159 | |
| Coexpression | HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_7DY_UP | 1.74e-05 | 27 | 49 | 3 | M41009 | |
| Coexpression | GSE36888_UNTREATED_VS_IL2_TREATED_TCELL_2H_DN | 3.49e-05 | 199 | 49 | 5 | M8736 | |
| CoexpressionAtlas | Mesoderm Day 15_vs_Mesoderm Day 30-Confounder_removed-fold2.0_adjp0.05 | TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 1.11e-12 | 90 | 53 | 9 | PCBC_ratio_MESO-15_vs_MESO-30_cfr-2X-p05 |
| CoexpressionAtlas | Endoderm Differentiated Cells-reprogram_OSKM-L_vs_Endoderm Differentiated Cells-reprogram_NA-Confounder_removed-fold2.0_adjp0.05 | TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 2.63e-09 | 213 | 53 | 9 | PCBC_ratio_DE_from-OSKM-L_vs_DE_from-ESC_cfr-2X-p05 |
| CoexpressionAtlas | Endoderm Differentiated Cells-method_mRNA_vs_Endoderm Differentiated Cells-method_NA-Confounder_removed-fold2.0_adjp0.05 | TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 2.63e-09 | 213 | 53 | 9 | PCBC_ratio_DE_from-mRNA_vs_DE_from-ESC_cfr-2X-p05 |
| CoexpressionAtlas | DE cord blood_vs_DE blastocyst-Confounder_removed-fold2.0_adjp0.05 | TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 8.01e-09 | 242 | 53 | 9 | PCBC_ratio_DE cord blood_vs_DE blastocyst_cfr-2X-p05 |
| CoexpressionAtlas | Mesoderm Day 5-reprogram_OSKM-L_vs_Mesoderm Day 5-reprogram_NA-Confounder_removed-fold2.0_adjp0.05 | TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 2.92e-08 | 281 | 53 | 9 | PCBC_ratio_MESO-5_from-OSKM-L_vs_MESO-5_from-ESC_cfr-2X-p05 |
| CoexpressionAtlas | Mesoderm Day 5-method_mRNA_vs_Mesoderm Day 5-method_NA-Confounder_removed-fold2.0_adjp0.05 | TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 2.92e-08 | 281 | 53 | 9 | PCBC_ratio_MESO-5_from-mRNA_vs_MESO-5_from-ESC_cfr-2X-p05 |
| CoexpressionAtlas | Mesoderm Day 5_vs_Endoderm Differentiated Cells-Confounder_removed-fold2.0_adjp0.05 | TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 8.87e-08 | 320 | 53 | 9 | PCBC_ratio_MESO-5_vs_DE_cfr-2X-p05 |
| CoexpressionAtlas | Mesoderm Day 15_vs_Mesoderm Day 5-Confounder_removed-fold2.0_adjp0.05 | TBC1D3 CLCN3 TBC1D3H TBC1D3L TBC1D3D GPAM TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 4.58e-05 | 1049 | 53 | 11 | PCBC_ratio_MESO-15_vs_MESO-5_cfr-2X-p05 |
| CoexpressionAtlas | Mesoderm Day 5_vs_Pluripotent Stem Cells-Confounder_removed-fold2.0_adjp0.05 | FOXJ2 TBC1D3 TBC1D3H TBC1D3L TBC1D3D DTNA TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 1.07e-04 | 1153 | 53 | 11 | PCBC_ratio_MESO-5_vs_SC_cfr-2X-p05 |
| CoexpressionAtlas | Ectoderm Differentiated Cells_vs_Endoderm Differentiated Cells-Confounder_removed-fold2.0_adjp0.05 | ACTR1B TBC1D3 TBC1D3H TBC1D3L TBC1D3D TBC1D3G TBC1D3C TBC1D3B TBC1D3K TBC1D3F | 2.83e-04 | 1075 | 53 | 10 | PCBC_ratio_ECTO_vs_DE_cfr-2X-p05 |
| ToppCell | LA-03._Atrial_Cardiomyocyte|World / Chamber and Cluster_Paper | 2.95e-06 | 188 | 53 | 5 | 6d249fe92d51a19da19ec14bb2262d394255d577 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c04-ANXA2|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.23e-05 | 163 | 53 | 4 | ce07bc424ef99c547588b07f5c8b39ff0773ca9b | |
| ToppCell | COVID-19-Heart-CM_+_Macrophage|COVID-19 / Disease (COVID-19 only), tissue and cell type | 4.99e-05 | 170 | 53 | 4 | 3f15242a1d3e4e9871d9170b2ef05842fb609c29 | |
| ToppCell | PND07-Immune-Immune_Myeloid-Monocytic-Macrophage-AM-AM_G2M|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.10e-05 | 171 | 53 | 4 | 845f312f8cbe29d820da25f0e6d75deb382bbfd8 | |
| ToppCell | COVID-19-Heart-CM_3|COVID-19 / Disease (COVID-19 only), tissue and cell type | 5.71e-05 | 176 | 53 | 4 | 9df7a124ebafb0087da0cda133a394275d7bed81 | |
| ToppCell | COVID-19-Heart-CM_+_EC_+_Pericyte|COVID-19 / Disease (COVID-19 only), tissue and cell type | 6.36e-05 | 181 | 53 | 4 | 719eb532453ab7cd7893726885bc75d74a10b21e | |
| ToppCell | COVID-19-Heart-CM_3|Heart / Disease (COVID-19 only), tissue and cell type | 6.50e-05 | 182 | 53 | 4 | 287fcc3897ae08841f6f85ae6c9cef16f75b1dd1 | |
| ToppCell | LV-15._Ventricular_Cardiomyocyte_III|LV / Chamber and Cluster_Paper | 6.78e-05 | 184 | 53 | 4 | ab7a1620c14a9d9b6be1b47c559931e345e9eef8 | |
| ToppCell | COVID-19-Heart-CM_2|COVID-19 / Disease (COVID-19 only), tissue and cell type | 6.92e-05 | 185 | 53 | 4 | 549eeb521c3985bff396ea0f202db21822efa51f | |
| ToppCell | LV-15._Ventricular_Cardiomyocyte_III|World / Chamber and Cluster_Paper | 6.92e-05 | 185 | 53 | 4 | 6baccb26f999145e51b91d94315bf8d4655bef31 | |
| ToppCell | RV-06._Ventricular_Cardiomyocyte_II|World / Chamber and Cluster_Paper | 7.52e-05 | 189 | 53 | 4 | 5e80c47f63980904c4c1ff02c201b67b456a0974 | |
| ToppCell | COVID-19-Heart|COVID-19 / Disease (COVID-19 only), tissue and cell type | 7.68e-05 | 190 | 53 | 4 | 918ad5037881212008f9f69d5df5da91fd01422c | |
| ToppCell | COVID-19-Heart-CM_4|Heart / Disease (COVID-19 only), tissue and cell type | 7.68e-05 | 190 | 53 | 4 | 3729648a17093b438398b82e32bbccc3af7b8c5d | |
| ToppCell | COVID-19-Heart-CM_+_EC_+_Pericyte|Heart / Disease (COVID-19 only), tissue and cell type | 8.15e-05 | 193 | 53 | 4 | dd5378a1ef8eb0eda9a3aae62f3c2f3a1402bda0 | |
| ToppCell | COVID-19-Heart-CM_1|Heart / Disease (COVID-19 only), tissue and cell type | 8.49e-05 | 195 | 53 | 4 | f1ef50331eda8f1239dba6ea970df4eaccf032f1 | |
| ToppCell | COVID-19-Heart-CM_2|Heart / Disease (COVID-19 only), tissue and cell type | 8.49e-05 | 195 | 53 | 4 | 75fc81bddb246dca3b437fb60827b1d4fe416405 | |
| ToppCell | Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 9.00e-05 | 198 | 53 | 4 | 22e766df1276c5b14aa0d83f434f47140ebb98ea | |
| ToppCell | control-unassigned|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 9.18e-05 | 199 | 53 | 4 | 50e2da35edff1aadef939cfbd4549f73c1a07717 | |
| ToppCell | control-unassigned|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 9.18e-05 | 199 | 53 | 4 | 5db7c8089172ac8e796613b3cef618d87007a0ab | |
| ToppCell | Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Drd1-Excitatory_Neuron.Gad1Gad2.Drd1-Nfib_(Amygdala)-|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.28e-04 | 82 | 53 | 3 | 1ca848a18463b1344e23e3ad1b5d01ae27c00586 | |
| ToppCell | Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Drd1-Excitatory_Neuron.Gad1Gad2.Drd1-Nfib_(Amygdala)|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.28e-04 | 82 | 53 | 3 | ab081620b6113f843fede23da0a18720111ffc7c | |
| Computational | Neighborhood of DMPK | 3.95e-04 | 175 | 22 | 4 | MORF_DMPK | |
| Computational | Neighborhood of PRKCA | 4.49e-04 | 181 | 22 | 4 | MORF_PRKCA | |
| Computational | Neighborhood of MAP2K7 | 4.49e-04 | 181 | 22 | 4 | MORF_MAP2K7 | |
| Computational | Neighborhood of CTSB | 5.08e-04 | 187 | 22 | 4 | MORF_CTSB | |
| Computational | Neighborhood of IFNA1 | 7.18e-04 | 205 | 22 | 4 | MORF_IFNA1 | |
| Computational | Neighborhood of PTPRR | 1.12e-03 | 102 | 22 | 3 | MORF_PTPRR | |
| Computational | Neighborhood of PTPRB | 1.59e-03 | 254 | 22 | 4 | MORF_PTPRB | |
| Computational | Neighborhood of MAGEA8 | 1.74e-03 | 260 | 22 | 4 | MORF_MAGEA8 | |
| Computational | Neighborhood of FSHR | 2.25e-03 | 279 | 22 | 4 | MORF_FSHR | |
| Computational | Neighborhood of CDH4 | 2.56e-03 | 136 | 22 | 3 | MORF_CDH4 | |
| Computational | Neighborhood of CAMK4 | 2.59e-03 | 290 | 22 | 4 | MORF_CAMK4 | |
| Computational | Neighborhood of MLLT10 | 2.99e-03 | 302 | 22 | 4 | MORF_MLLT10 | |
| Computational | Neighborhood of SUPT3H | 4.03e-03 | 328 | 22 | 4 | MORF_SUPT3H | |
| Computational | Neighborhood of ATF2 | 4.12e-03 | 330 | 22 | 4 | MORF_ATF2 | |
| Drug | dihydrocytochalasin B | 5.71e-06 | 58 | 46 | 4 | CID000003064 | |
| Disease | glycerol kinase deficiency (implicated_via_orthology) | 5.93e-06 | 3 | 42 | 2 | DOID:0060363 (implicated_via_orthology) | |
| Disease | cholesteryl esters to total lipids in IDL percentage | 5.02e-05 | 50 | 42 | 3 | EFO_0022247 | |
| Disease | cholesterol in IDL measurement | 7.83e-05 | 58 | 42 | 3 | EFO_0021899 | |
| Disease | total lipids in IDL | 8.67e-05 | 60 | 42 | 3 | EFO_0022161 | |
| Disease | cholesterol to total lipids in IDL percentage | 8.67e-05 | 60 | 42 | 3 | EFO_0022233 | |
| Disease | free cholesterol in IDL measurement | 9.11e-05 | 61 | 42 | 3 | EFO_0022181 | |
| Disease | triglycerides to total lipids in IDL percentage | 1.00e-04 | 63 | 42 | 3 | EFO_0022329 | |
| Disease | phospholipids:total lipids ratio, intermediate density lipoprotein measurement | 1.21e-04 | 67 | 42 | 3 | EFO_0008595, EFO_0020946 | |
| Disease | triglycerides to phosphoglycerides ratio | 1.26e-04 | 68 | 42 | 3 | EFO_0022327 | |
| Disease | triglycerides to total lipids in very small VLDL percentage | 1.32e-04 | 69 | 42 | 3 | EFO_0022341 | |
| Disease | free cholesterol to total lipids in large LDL percentage | 1.62e-04 | 74 | 42 | 3 | EFO_0022280 | |
| Disease | monounsaturated fatty acids; 16:1, 18:1 measurement | 1.89e-04 | 78 | 42 | 3 | EFO_0022187 | |
| Disease | cholesteryl ester measurement, intermediate density lipoprotein measurement | 3.28e-04 | 94 | 42 | 3 | EFO_0008595, EFO_0010351 | |
| Disease | lipid measurement, intermediate density lipoprotein measurement | 3.49e-04 | 96 | 42 | 3 | EFO_0004529, EFO_0008595 | |
| Disease | CCL4 measurement | 3.70e-04 | 20 | 42 | 2 | EFO_0004751 | |
| Disease | total cholesterol measurement, intermediate density lipoprotein measurement | 3.82e-04 | 99 | 42 | 3 | EFO_0004574, EFO_0008595 | |
| Disease | docosahexaenoic acid to total fatty acids percentage | 4.08e-04 | 21 | 42 | 2 | EFO_0022262 | |
| Disease | cholesteryl esters:total lipids ratio, intermediate density lipoprotein measurement | 4.30e-04 | 103 | 42 | 3 | EFO_0008595, EFO_0020944 | |
| Disease | free cholesterol measurement, intermediate density lipoprotein measurement | 4.42e-04 | 104 | 42 | 3 | EFO_0008591, EFO_0008595 | |
| Disease | cholesterol:total lipids ratio, intermediate density lipoprotein measurement | 6.87e-04 | 121 | 42 | 3 | EFO_0008595, EFO_0020943 | |
| Disease | triglycerides:total lipids ratio, intermediate density lipoprotein measurement | 7.91e-04 | 127 | 42 | 3 | EFO_0008595, EFO_0020947 | |
| Disease | cholesteryl esters to total lipids in large LDL percentage | 8.96e-04 | 31 | 42 | 2 | EFO_0022249 | |
| Disease | macrophage inflammatory protein 1b measurement | 9.64e-04 | 136 | 42 | 3 | EFO_0008219 | |
| Disease | free cholesterol measurement, low density lipoprotein cholesterol measurement | 9.85e-04 | 137 | 42 | 3 | EFO_0004611, EFO_0008591 | |
| Disease | triglyceride measurement, physical activity | 1.08e-03 | 34 | 42 | 2 | EFO_0003940, EFO_0004530 | |
| Disease | triglyceride measurement, phospholipid measurement | 1.18e-03 | 146 | 42 | 3 | EFO_0004530, EFO_0004639 | |
| Disease | non-alcoholic fatty liver disease (implicated_via_orthology) | 1.21e-03 | 36 | 42 | 2 | DOID:0080208 (implicated_via_orthology) | |
| Disease | triglycerides:total lipids ratio, low density lipoprotein cholesterol measurement | 1.28e-03 | 150 | 42 | 3 | EFO_0004611, EFO_0020947 | |
| Disease | degree of unsaturation measurement | 1.42e-03 | 39 | 42 | 2 | EFO_0022261 | |
| Disease | docosahexaenoic acid measurement, fatty acid measurement | 1.49e-03 | 40 | 42 | 2 | EFO_0005110, EFO_0007761 | |
| Disease | cholesterol to total lipids in large VLDL percentage | 1.88e-03 | 45 | 42 | 2 | EFO_0022236 | |
| Disease | cholesteryl esters to total lipids in small VLDL percentage | 2.23e-03 | 49 | 42 | 2 | EFO_0022256 | |
| Disease | triglycerides to total lipids in medium LDL percentage | 2.32e-03 | 50 | 42 | 2 | EFO_0022334 | |
| Disease | polyunsaturated fatty acids to total fatty acids percentage | 2.32e-03 | 50 | 42 | 2 | EFO_0022303 | |
| Disease | triglycerides to total lipids in large LDL percentage | 2.41e-03 | 51 | 42 | 2 | EFO_0022331 | |
| Disease | free cholesterol in large LDL measurement | 2.41e-03 | 51 | 42 | 2 | EFO_0022176 | |
| Disease | polyunsaturated fatty acids to monounsaturated fatty acids ratio | 2.41e-03 | 51 | 42 | 2 | EFO_0022302 | |
| Disease | cholesterol to total lipids in small VLDL percentage | 2.41e-03 | 51 | 42 | 2 | EFO_0022242 | |
| Disease | triglycerides to total lipids in very large VLDL percentage | 2.60e-03 | 53 | 42 | 2 | EFO_0022340 | |
| Disease | free cholesterol to total lipids in small LDL percentage | 2.60e-03 | 53 | 42 | 2 | EFO_0022286 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| ILASLDTFKKMWVSK | 346 | P42025 | |
| KSSTLIIQSMFRKWK | 1421 | Q8IZT6 | |
| WLSALTFKTLERMKK | 851 | Q6IE37 | |
| KFWMTGLSKTYKSHL | 551 | Q8NFG4 | |
| SEIRYSTWKKAVMKS | 496 | Q14409 | |
| RYDKKYSWDVKSLVM | 36 | Q08623 | |
| ERKSSRDKELYAWMK | 1876 | Q15652 | |
| SMRAASLKDKWGLSY | 3596 | Q2LD37 | |
| SLAYQRMSWEALKKS | 151 | Q9HCG8 | |
| KTWFDSEKKMKYLSL | 1221 | Q5CZC0 | |
| SEEKMSVSTWSRKKY | 3466 | Q5CZC0 | |
| ELLMLKLKWKSDSYF | 401 | P06858 | |
| WSLVSYMDKKSTAEK | 296 | Q8IXT1 | |
| STWKKYQEAMKTSLG | 26 | Q9UHL3 | |
| IKFWTAMFSDKKYLT | 151 | Q8N8J0 | |
| SSPAKKMTLSEIYRW | 81 | Q9P0K8 | |
| LSWSFRNLYKSMLEK | 251 | Q9P0K8 | |
| SWKGYSENMRKLRKT | 726 | Q8WY54 | |
| TEVMWYKDGKKLSSS | 1011 | Q5VST9 | |
| SEIRYATWKKAVMKS | 496 | Q14410 | |
| LKKYMEDRSKTTNTW | 86 | Q9NVQ4 | |
| ESEIRYSTWKKAVMK | 501 | P32189 | |
| ILASLDTFKKMWVSK | 346 | P61163 | |
| MKEYTSWKSPAKKLT | 286 | Q9Y4J8 | |
| MRIKLWEEIKSAKYS | 146 | Q8NA03 | |
| KYRSSSKMKSPDWLC | 6866 | Q8NDH2 | |
| MSLWKKTVYRSLCLA | 1 | Q8NFL0 | |
| LYSTWKKYQEAMKTS | 101 | P0C7A2 | |
| YSSRKAKRKMWQLVD | 246 | A5PLK6 | |
| WNFTKIMKSKYRSLS | 701 | Q13393 | |
| AKLFLLKWSFYSSMV | 846 | P22670 | |
| LQYYTWSEKKMELSK | 186 | Q15573 | |
| SATLKWKESLMSRKR | 46 | Q9HCL2 | |
| KWMKYGYTSSKLSVR | 126 | O43699 | |
| MLADWTKYRSTKKLS | 81 | Q86UD7 | |
| MLGDWEKYKSSRKLI | 81 | B9A6J9 | |
| IKFWTAMFSDKKYLT | 151 | A4QPH2 | |
| KKESAWEMTKSLYDA | 111 | P51790 | |
| KESMWYRKLKVFSGT | 151 | Q96PV4 | |
| MLGDWEKYKSSRKLI | 81 | A6NDS4 | |
| MLGDWEKYKSSRKLI | 81 | P0C7X1 | |
| RWYKDRDALMKSSKV | 171 | P52740 | |
| KSWMNLKSISPSYKT | 816 | Q8NBP0 | |
| TDYWKKMAKVLRSAG | 126 | Q9NQW7 | |
| NVDASVMYRKWKESK | 141 | P49427 | |
| MLGDWEKYKSSRKLI | 81 | A6NER0 | |
| RNTERSKDWYKTMFK | 386 | Q9BX66 | |
| MLGDWEKYKSSRKLI | 81 | A0A087X179 | |
| MLADWTKYRSTKKLS | 81 | Q2M2D7 | |
| MLGDWEKYKSSRKLI | 81 | A0A087WVF3 | |
| MLSDSKLWKGARSVY | 356 | Q8IWV8 | |
| MLGDWEKYKSSRKLI | 81 | Q6DHY5 | |
| MLGDWEKYKSSRKLI | 81 | Q8IZP1 | |
| MLGDWEKYKSSRKLI | 81 | A0A087X1G2 | |
| MLGDWEKYKSSRKLI | 81 | A0A087WXS9 | |
| MLGDWEKYKSSRKLI | 81 | Q6IPX1 | |
| KRWAMKVFSSLKSNE | 346 | Q86W24 | |
| MNKRLYTEAWDKDKT | 2961 | P20929 |